Finanzen von Enveric Biosciences Inc (ENVB)ENVBEnveric Biosciences Inc

Evaluating the bottom line, Enveric Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -235.48%, provide a clear picture of how effectively ENVB converts its operational activities into shareholder value.

In the context of the broader market, ENVB competes directly with industry leaders such as NAII and BNKK. With a market capitalization of $6.32M, it holds a significant position in the sector. When comparing efficiency, ENVB's gross margin of N/A stands against NAII's 5.00% and BNKK's 33.61%. Such benchmarking helps identify whether Enveric Biosciences Inc is trading at a premium or discount relative to its financial performance.

Enveric Biosciences has shown a consistent pattern of negative earnings, with a projected net income loss of -$4,040,207 in Q4 2025 and a gross profit of $0 in Q4 2024. The company has a current ratio of 11.67, indicating good short-term liquidity, but ongoing losses raise concerns about sustainability.